Manas Mishra has covered the healthcare and pharmaceuticals sector since 2017. He joined Norstella from Reuters, where he spent 8 years covering a range of breaking news stories ranging from vaccine development during the peak of the COVID-19 pandemic, to the killing of UnitedHealthcare CEO Brian Thompson. Manas was the Editor-in-Charge of the Bangalore health and pharmaceuticals team at Reuters between 2022-2025. When not looking for stories, Manas enjoys attending rock and metal concerts, swimming and reading science fiction.
Latest from Manas Mishra
IO Biotech will need to conduct a fresh registrational study for melanoma vaccine hopeful Cylembio, which one analyst fears could result in a delay of more than three years to its launch plans.
Genmab is to acquire Merus for $8bn to secure petosemtamab, a promising head and neck cancer therapy, as it prepares for post-Darzalex revenue decline.
A complete response letter for a PET imaging agent demonstrates the rare but serious risks taken on by both parties in a royalty monetization deal.
The biotech is to cut a quarter of its workforce, extending its cash runway to Q2 2026 as it plans a Phase II study for its live biotherapeutic to prevent bloodstream infections.
The US FDA's long-awaited draft guidance could help streamline dose-finding studies for the fast-growing class of radiopharmaceutical therapies.
Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.